{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T03:11:28Z","timestamp":1761707488604},"reference-count":53,"publisher":"Oxford University Press (OUP)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2000,9]]},"DOI":"10.1093\/qjmed\/93.9.567","type":"journal-article","created":{"date-parts":[[2002,7,26]],"date-time":"2002-07-26T18:32:47Z","timestamp":1027708367000},"page":"567-574","source":"Crossref","is-referenced-by-count":25,"title":["Identifying patients at risk for coronary heart disease: implications from trials of lipid\u2010lowering drug therapy"],"prefix":"10.1093","volume":"93","author":[{"given":"C.G.","family":"Isles","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.R.","family":"Paterson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2000,9]]},"reference":[{"key":"key\n\t\t\t\t20170413035053_R1","unstructured":"Coronary heart disease statistics. British Heart Foundation Database 1998. Published by British Heart Foundation, 14 Fitzhardinge Street, London W1H 4DH. Website: www.bhf.org.uk"},{"key":"key\n\t\t\t\t20170413035053_R2","doi-asserted-by":"crossref","unstructured":"Wood D, De Backer G, Faergeman O, Graham I, Mancia G, Py\u00f6r\u00e4l\u00e4 K. Members of the Second Joint Task Force of European and other Societies on Coronary Prevention: Prevention of coronary heart disease in clinical practice. Eur Heart J1998; 19:1434\u2013503.","DOI":"10.1053\/euhj.1998.1243"},{"key":"key\n\t\t\t\t20170413035053_R3","unstructured":"Working Party for the British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, British Diabetic Association. Joint British Recommendations on prevention of coronary heart disease in clinical practice. Heart1998; 80(Suppl.\u20092):S1\u2013S29."},{"key":"key\n\t\t\t\t20170413035053_R4","unstructured":"Final Consensus Statement. Consensus Conference on lipid lowering to prevent vascular events. Proc Roy Coll Phys Edin1999; 29(Suppl.\u20095):2\u20134."},{"key":"key\n\t\t\t\t20170413035053_R5","unstructured":"Scottish Intercollegiate Guidelines Network. Lipids and the primary prevention of coronary heart disease. SIGN Publication No.\u200940. Edinburgh, Royal College of Physicians Edinburgh,1999."},{"key":"key\n\t\t\t\t20170413035053_R6","unstructured":"Scottish Intercollegiate Guidelines Network. Secondary prevention of coronary heart disease following myocardial infarction. SIGN Publication No.\u200941. Edinburgh, Royal College of Physicians Edinburgh,1999."},{"key":"key\n\t\t\t\t20170413035053_R7","unstructured":"Effective Health Care. Cholesterol and coronary heart disease: screening and treatment, vol.\u20094 (No.\u20091). University of York, NHS Centre for Reviews and Dissemination,1998:1\u201316."},{"key":"key\n\t\t\t\t20170413035053_R8","doi-asserted-by":"crossref","unstructured":"Adult Treatment Panel II. Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. JAMA1993; 269:3015\u201323.","DOI":"10.1001\/jama.269.23.3015"},{"key":"key\n\t\t\t\t20170413035053_R9","doi-asserted-by":"crossref","unstructured":"Neaton JD, Wentworth D. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316\u2009099 white men. Multiple Risk Factor Intervention Group. Arch Intern Med1992; 152:56\u201364.","DOI":"10.1001\/archinte.1992.00400130082009"},{"key":"key\n\t\t\t\t20170413035053_R10","doi-asserted-by":"crossref","unstructured":"Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12 year cardiovascular mortality for men screened in the Multiple Risk Factor Interventions Trial. Diabetes Care1993; 16:434\u201344.","DOI":"10.2337\/diacare.16.2.434"},{"key":"key\n\t\t\t\t20170413035053_R11","doi-asserted-by":"crossref","unstructured":"Abbott RD, Wilson PW, Kannel WB, Castelli WP. High density lipoprotein cholesterol, total cholesterol screening, and myocardial infarction. The Framingham Study. Arteriosclerosis1988; 8:207\u201311.","DOI":"10.1161\/01.ATV.8.3.207"},{"key":"key\n\t\t\t\t20170413035053_R12","unstructured":"Manninen V, Elo MO, Frick MH, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA1988; 260:641\u201351."},{"key":"key\n\t\t\t\t20170413035053_R13","doi-asserted-by":"crossref","unstructured":"Hodis HN, Mack WN. Triglyceride\u2010rich lipoproteins and the progression of coronary artery disease. Curr Opin Lipidol1995; 6:209\u201314.","DOI":"10.1097\/00041433-199508000-00004"},{"key":"key\n\t\t\t\t20170413035053_R14","doi-asserted-by":"crossref","unstructured":"Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet1994; 344:1383\u20139.","DOI":"10.1016\/S0140-6736(94)90566-5"},{"key":"key\n\t\t\t\t20170413035053_R15","doi-asserted-by":"crossref","unstructured":"Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown, L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E, for the Cholesterol and Recurrent Events Trial investigators: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med1996; 335:1001\u20139.","DOI":"10.1056\/NEJM199610033351401"},{"key":"key\n\t\t\t\t20170413035053_R16","doi-asserted-by":"crossref","unstructured":"The Long\u2010Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med1998; 339:1349\u201357.","DOI":"10.1056\/NEJM199811053391902"},{"key":"key\n\t\t\t\t20170413035053_R17","doi-asserted-by":"crossref","unstructured":"Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, McKillop JH, Packard CJ, for the West of Scotland Coronary Prevention Study Group: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med1995; 333:1301\u20137.","DOI":"10.1056\/NEJM199511163332001"},{"key":"key\n\t\t\t\t20170413035053_R18","doi-asserted-by":"crossref","unstructured":"Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS\/TexCAPS. JAMA1998; 279:1615\u201322.","DOI":"10.1001\/jama.279.20.1615"},{"key":"key\n\t\t\t\t20170413035053_R19","doi-asserted-by":"crossref","unstructured":"Gould AL, Rossouw JE, Santanello NC, Heyse JF, Furberg CD. Cholesterol reduction yields clinical benefit: impact of statin trials. Circulation1998; 97:946\u201352.","DOI":"10.1161\/01.CIR.97.10.946"},{"key":"key\n\t\t\t\t20170413035053_R20","unstructured":"Baigent C, Armitage J. Cholesterol reduction among patients at increased risk of coronary heart disease. Proc Roy Coll Phys Edin1999; 29(Suppl.\u20095):10\u201315."},{"key":"key\n\t\t\t\t20170413035053_R21","doi-asserted-by":"crossref","unstructured":"Miettinen TA, Pyorala K, Olsson AG, Musliner TA, Cook TJ, Faergeman O, et al. Cholesterol lowering therapy in women and elderly patients with myocardial infarction or angina pectoris. Findings from the Scandinavian Simvastatin Survival Study. Circulation1997; 96:4211\u201318.","DOI":"10.1161\/01.CIR.96.12.4211"},{"key":"key\n\t\t\t\t20170413035053_R22","doi-asserted-by":"crossref","unstructured":"Lewis SJ, Sacks FM, Mitchell JS, East C, Glasser S, Kell S, et al. Effect of pravastatin on cardiovascular events in women after myocardial infarction: the Cholesterol and Recurrent Events (CARE) Trial. JACC1998; 32:140\u20136.","DOI":"10.1016\/S0735-1097(98)00202-2"},{"key":"key\n\t\t\t\t20170413035053_R23","doi-asserted-by":"crossref","unstructured":"Lewis SJ, Moye LA, Sacks F, Johnstone DE, Timmis G, Mitchell J, et al. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the normal range. Results from the CARE trial. Ann Intern Med1998; 129:681\u20139.","DOI":"10.7326\/0003-4819-129-9-199811010-00002"},{"key":"key\n\t\t\t\t20170413035053_R24","doi-asserted-by":"crossref","unstructured":"Pyorala K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study. Diabetes Care1997; 20:614\u201320.","DOI":"10.2337\/diacare.20.4.614"},{"key":"key\n\t\t\t\t20170413035053_R25","doi-asserted-by":"crossref","unstructured":"Haffner SM, Alexander CM, Cook TJ, Boccuzzi SJ, Musliner TA, Pedersen TR, et al. Reduced coronary events in simvastatin treated patients with coronary heart disease and diabetes or impaired fasting glucose levels. Subgroup analyses in the Scandinavian Simvastatin Survival Study. Arch Int Med1999; 159:2661\u20137.","DOI":"10.1001\/archinte.159.22.2661"},{"key":"key\n\t\t\t\t20170413035053_R26","doi-asserted-by":"crossref","unstructured":"Goldberg RB, Mellies MJ, Sacks FM, Moye LA, Howard BV, Howard WJ, et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose interolant myocardial infarction survivors with average cholesterol levels. Subgroup analyses in the CARE trial. Circulation1998; 98:2513\u201319.","DOI":"10.1161\/01.CIR.98.23.2513"},{"key":"key\n\t\t\t\t20170413035053_R27","doi-asserted-by":"crossref","unstructured":"Blauw GJ, Lagaay AM, Smelt AH, Westendorp RG. Stroke, statins and cholesterol. A meta\u2010analysis of randomised placebo controlled double blind trials with HMG\u2010CoA reductase inhibitors. Stroke1997; 28:946\u201350.","DOI":"10.1161\/01.STR.28.5.946"},{"key":"key\n\t\t\t\t20170413035053_R28","doi-asserted-by":"crossref","unstructured":"West of Scotland Coronary Prevention Study Group. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation1998; 97:1440\u20135.","DOI":"10.1161\/01.CIR.97.15.1440"},{"key":"key\n\t\t\t\t20170413035053_R29","doi-asserted-by":"crossref","unstructured":"Pedersen TR, Olsson AG, Faergeman O, Kjekshus J, Wedel H, Berg K, Wilhelmsen L, Haghfelt T, Thorgeirsson G, Py\u00f6r\u00e4l\u00e4 K, Miettinen T, Christophersen B, Tobert JA, Musliner TA, Cook TJ, for the Scandinavian Simvastatin Survival Study Group: Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation1998; 97:1453\u201360.","DOI":"10.1161\/01.CIR.97.15.1453"},{"key":"key\n\t\t\t\t20170413035053_R30","doi-asserted-by":"crossref","unstructured":"Scandinavian Simvastatin Survival Study Group. Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study. Lancet1995; 345:1274\u20135.","DOI":"10.1016\/S0140-6736(95)90926-5"},{"key":"key\n\t\t\t\t20170413035053_R31","doi-asserted-by":"crossref","unstructured":"Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high density lipoprotein cholesterol. N Engl J Med1999; 341:410\u201318.","DOI":"10.1056\/NEJM199908053410604"},{"key":"key\n\t\t\t\t20170413035053_R32","doi-asserted-by":"crossref","unstructured":"Frick MH, Elo MO, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Manninen V, M\u00e4enp\u00e4\u00e4 H, M\u00e4lk\u00f6nen M, M\u00e4ntt\u00e4ri M, Norola S, Pasternack A, Pikkarainen J, Romo M, Sj\u00f6blom T, Nikkil\u00e4 EA. Helsinki Heart Study: primary prevention trial with gemfibrozil in middle\u2010aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med1987; 317:1237\u201345.","DOI":"10.1056\/NEJM198711123172001"},{"key":"key\n\t\t\t\t20170413035053_R33","doi-asserted-by":"crossref","unstructured":"Ramsey LE, Yeo WW, Jackson PR. Dietary reduction of serum cholesterol concentration: time to think again. Br Med J1991; 303:953\u20137.","DOI":"10.1136\/bmj.303.6808.953"},{"key":"key\n\t\t\t\t20170413035053_R34","doi-asserted-by":"crossref","unstructured":"Koren MJ, Smith DG, Hunninghake DB, Davidson MH, McKenney JM, Weiss SR, Schrott HG, Henley Jr RW, Tresh P, McLain RW, Bakker\u2010Arkema RG, Black DM. The cost of reaching National Cholesterol Education Program (NCEP) goals in hypercholesterolaemic patients. A comparison of atorvastatin, simvastatin, lovastatin and fluvastatin. PharmacoEconomics1998; 14:59\u201370.","DOI":"10.2165\/00019053-199814010-00006"},{"key":"key\n\t\t\t\t20170413035053_R35","unstructured":"Witztum JL. Drugs used in the treatment of hyperlipoproteinemias. In: Hardman JG, Gilman AG, Limbird LE, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 9th edn. New York, McGraw\u2010Hill,1996:875\u201397."},{"key":"key\n\t\t\t\t20170413035053_R36","doi-asserted-by":"crossref","unstructured":"Guyton JR, Goldberg AC, Kreisberg RA, Sprecher DL, Superko HR, O'Connor CM. Effectiveness of once\u2010nightly dosing of extended\u2010release niacin alone and in combination for hypercholesterolemia. Am J Cardiol1998; 82:737\u201343.","DOI":"10.1016\/S0002-9149(98)00448-2"},{"key":"key\n\t\t\t\t20170413035053_R37","doi-asserted-by":"crossref","unstructured":"Ramsey LE, Williams B, Johnston GD, MacGregor GA, Poston L, Potter JF, Poulter NR, Russell G. Guidelines for management of hypertension: report of the Third Working Party of the British Hypertension Society. J Hum Hypertens1999; 13:569\u201392.","DOI":"10.1038\/sj.jhh.1000917"},{"key":"key\n\t\t\t\t20170413035053_R38","doi-asserted-by":"crossref","unstructured":"The sixth report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure. Arch Intern Med1997; 157:2413\u201346.","DOI":"10.1001\/archinte.1997.00440420033005"},{"key":"key\n\t\t\t\t20170413035053_R39","doi-asserted-by":"crossref","unstructured":"GISSI Prevenzione Investigators. Dietary supplementation with n\u20103 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI\u2010Prevenzione Trial. Lancet1999; 354:447\u201355.","DOI":"10.1016\/S0140-6736(99)07072-5"},{"key":"key\n\t\t\t\t20170413035053_R40","doi-asserted-by":"crossref","unstructured":"The Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of an ACE inhibitor, Ramipril, on deaths from cardiovascular causes, myocardial infarction and stroke in high risk patients. N Engl J Med2000; 342:145\u201353.","DOI":"10.1056\/NEJM200001203420301"},{"key":"key\n\t\t\t\t20170413035053_R41","doi-asserted-by":"crossref","unstructured":"Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E, for the Heart and Estrogen\/progestin Replacement Study (HERS) Research Group: Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA1998; 280:605\u201313.","DOI":"10.1001\/jama.280.7.605"},{"key":"key\n\t\t\t\t20170413035053_R42","doi-asserted-by":"crossref","unstructured":"Lonn EM, Yusuf S. Emerging approaches in preventing cardiovascular disease. BMJ1999; 318:1337\u201341.","DOI":"10.1136\/bmj.318.7194.1337"},{"key":"key\n\t\t\t\t20170413035053_R43","doi-asserted-by":"crossref","unstructured":"Moghadasian MH, Frohlich JJ. Effects of dietary phytosterols on cholesterol metabolism and atherosclerosis: clinical and experimental evidence. Am J Med1999; 107:588\u201394.","DOI":"10.1016\/S0002-9343(99)00285-5"},{"key":"key\n\t\t\t\t20170413035053_R44","unstructured":"Cholesterol lowering ingredients in foods: nutrition advice to subgroups of the population. London, Department of Health, Letter to Health Professionals, 7 Jan2000."},{"key":"key\n\t\t\t\t20170413035053_R45","doi-asserted-by":"crossref","unstructured":"Clarke R, Collins R. Can dietary supplements with folic acid or vitamin B6 reduce cardiovascular risk? Design of clinical trials to test the homocysteine hypothesis of vascular disease. J Cardiovasc Risk1998; 5:249\u201355.","DOI":"10.1097\/00043798-199808000-00007"},{"key":"key\n\t\t\t\t20170413035053_R46","unstructured":"Haq IU, Jackson PR, Yeo WW, Ramsay LE. A comparison of methods for targeting CHD risk for primary prevention. Heart1997; 77(Suppl. 1):36."},{"key":"key\n\t\t\t\t20170413035053_R47","unstructured":"Dyslipidaemia Advisory Group on behalf of the Scientific Committee of the National Heart Foundation of New Zealand. 1996 National Heart Foundation Guidelines for the assessment and management of dyslipidaemia. NZ Med J1996; 109:224\u201332."},{"key":"key\n\t\t\t\t20170413035053_R48","doi-asserted-by":"crossref","unstructured":"Isles CG, Ritchie LD, Murchie P, Norrie J. Risk assessment in primary prevention of coronary heart disease: a comparison of three scoring methods. Br Med J2000; 320:690\u20131.","DOI":"10.1136\/bmj.320.7236.690"},{"key":"key\n\t\t\t\t20170413035053_R49","doi-asserted-by":"crossref","unstructured":"Ridker PM, Glynn RJ, Hennekens CH. C reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation1998; 97:2007\u201311.","DOI":"10.1161\/01.CIR.97.20.2007"},{"key":"key\n\t\t\t\t20170413035053_R50","doi-asserted-by":"crossref","unstructured":"O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK, for the Cardiovascular Health Study Collaborative Research Group. Carotid artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. N Engl J Med1999; 340:14\u201322.","DOI":"10.1056\/NEJM199901073400103"},{"key":"key\n\t\t\t\t20170413035053_R51","doi-asserted-by":"crossref","unstructured":"Craig WY, Neveux LM, Palomaki GE, Cleveland MM, Haddow JE. Lipoprotein (a) as a risk factor for ischaemic heart disease: meta\u2010analysis of prospective studies. Clin Chem1998; 44:2301\u20136.","DOI":"10.1093\/clinchem\/44.11.2301"},{"key":"key\n\t\t\t\t20170413035053_R52","doi-asserted-by":"crossref","unstructured":"Lamarche B, Tchernof A, Moorjani S, Kantin B, Dagenais GR, Lupien PJ, et al. Small dense low density lipoprotein particles as a predictor of the risk of ischaemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Circulation1997; 95:69\u201375.","DOI":"10.1161\/01.CIR.95.1.69"},{"key":"key\n\t\t\t\t20170413035053_R53","doi-asserted-by":"crossref","unstructured":"Harjai KJ. Potential new cardiovascular risk factors: left ventricular hypertrophy, homocysteine, lipoprotein (a), triglycerides, oxidative stress and fibrinogen. Ann Intern Med1999; 131:376\u201386.","DOI":"10.7326\/0003-4819-131-5-199909070-00009"}],"container-title":["QJM: An International Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/qjmed\/article-pdf\/93\/9\/567\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,4]],"date-time":"2020-03-04T03:42:22Z","timestamp":1583293342000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/qjmed\/article-lookup\/doi\/10.1093\/qjmed\/93.9.567"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,9]]},"references-count":53,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2000,9]]},"published-print":{"date-parts":[[2000,9]]}},"URL":"https:\/\/doi.org\/10.1093\/qjmed\/93.9.567","relation":{},"ISSN":["1460-2393","1460-2725"],"issn-type":[{"value":"1460-2393","type":"electronic"},{"value":"1460-2725","type":"print"}],"subject":[],"published":{"date-parts":[[2000,9]]}}}